摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 2-azido-2-deoxy-D-galactopyranoside | 670249-18-0

中文名称
——
中文别名
——
英文名称
methyl 2-azido-2-deoxy-D-galactopyranoside
英文别名
methyl 2-azido-2-deoxy-galactopyranoside;methyl 2-azido-2-deoxy-α/β-D-galactopyranoside;(2R,3R,4R,5R)-5-azido-2-(hydroxymethyl)-6-methoxytetrahydro-2H-pyran-3,4-diol;(2R,3R,4R,5R)-5-azido-2-(hydroxymethyl)-6-methoxyoxane-3,4-diol
methyl 2-azido-2-deoxy-D-galactopyranoside化学式
CAS
670249-18-0
化学式
C7H13N3O5
mdl
——
分子量
219.197
InChiKey
QYZPIZZUWJKSTF-WLDMJGECSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.5
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    93.5
  • 氢给体数:
    3
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3

反应信息

  • 作为反应物:
    参考文献:
    名称:
    铜绿假单胞菌脂多糖外核心区糖型的常见三糖片段的合成
    摘要:
    报道了铜绿假单胞菌脂多糖外核心区糖型的常见三糖的首次合成。通过对β-(1→3)连接的6 - O-苄基-2-叠氮基-2-脱氧-3 - O -(- )进行高效的α-(1→4)-葡萄糖基化反应,可以制备出具有完全保护作用的三糖前体。2,3,4,6-四-O-乙酰基-β-d-吡喃葡萄糖基)-α-d-吡喃半乳糖苷。相反,糖基化的替代序列涉及与α-(1→4)连接的Glc-GalN 3的β-糖基化单位,没有导致目标三糖骨架。被保护的三糖前体的进一步O-脱乙酰基,叠氮基还原和脱苄基反应得到相应的三糖胺。后一种结构用于合成一系列三糖,其在GalN的C-2的氨基上带有乙酰基,1-丙氨酸或N-乙酰化的1-丙氨酸残基。
    DOI:
    10.1016/j.tetlet.2006.03.045
  • 作为产物:
    描述:
    methyl 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α/β-D-galactopyranoside 在 sodium methylate 作用下, 以 甲醇 为溶剂, 生成 methyl 2-azido-2-deoxy-D-galactopyranoside
    参考文献:
    名称:
    铜绿假单胞菌脂多糖外核心区糖型的常见三糖片段的合成
    摘要:
    报道了铜绿假单胞菌脂多糖外核心区糖型的常见三糖的首次合成。通过对β-(1→3)连接的6 - O-苄基-2-叠氮基-2-脱氧-3 - O -(- )进行高效的α-(1→4)-葡萄糖基化反应,可以制备出具有完全保护作用的三糖前体。2,3,4,6-四-O-乙酰基-β-d-吡喃葡萄糖基)-α-d-吡喃半乳糖苷。相反,糖基化的替代序列涉及与α-(1→4)连接的Glc-GalN 3的β-糖基化单位,没有导致目标三糖骨架。被保护的三糖前体的进一步O-脱乙酰基,叠氮基还原和脱苄基反应得到相应的三糖胺。后一种结构用于合成一系列三糖,其在GalN的C-2的氨基上带有乙酰基,1-丙氨酸或N-乙酰化的1-丙氨酸残基。
    DOI:
    10.1016/j.tetlet.2006.03.045
点击查看最新优质反应信息

文献信息

  • [EN] TARGETED PLASMA PROTEIN DEGRADATION<br/>[FR] DÉGRADATION CIBLÉE DE PROTÉINES DE PLASMA
    申请人:NOVARTIS AG
    公开号:WO2021156792A1
    公开(公告)日:2021-08-12
    The present invention is directed to the bifunctional compounds and the use of such bifunctional compounds to lower plasma levels of extracellular target molecules by lysosomal degradation. Such bifunctional compounds have a cell surface receptor ligand covalently linked to a ligand that is capable of binding to an extracellular target molecule (such as a ligand for a growth factor, a cytokine, a chemokine, a hormone, a neurotransmitter, a capsid, a soluble receptor, an extracellular secreted protein, an antibody, a lipoprotein, an exosome, a virus, a cell, or a plasma membrane protein), where the cell surface receptor is associated with receptor mediated endocytosis, including asialoglycoprotein receptor (ASGPR) mediated lysosomal degradation and mannose-6-phosphate (M6PR) mediated lysosomal degradation. Pharmaceutical compositions comprising such bifunctional compounds and methods of treating a disease or disorder mediated by an extracellular molecule using such bifunctional compounds are also provided herein.
    本发明涉及双功能化合物及利用这种双功能化合物通过溶酶体降解降低细胞外靶分子血浆平的用途。这种双功能化合物具有与细胞表面受体配体共价连接的配体,该配体能够结合到细胞外靶分子(例如生长因子、细胞因子、趋化因子、激素、神经递质、外壳蛋白、可溶性受体、细胞外分泌蛋白、抗体、脂蛋白、外泌体、病毒、细胞或血浆膜蛋白的配体),其中细胞表面受体与受体介导的内吞作用相关联,包括以阿斯利康蛋白受体(ASGPR)介导的溶酶体降解和甘露糖-6-磷酸(M6PR)介导的溶酶体降解。本文还提供了包括这种双功能化合物的药物组合物以及利用这种双功能化合物治疗通过细胞外分子介导的疾病或紊乱的方法。
  • Regioselective Glycosylation of Glucosamine and Galactosamine Derivates Using O-Pivaloyl Galactosyl Donors
    作者:Mathia Oßwald、Uwe Lang、Siglinde Friedrich-Bochnitschek、Waldemar Pfrengle、Horst Kunz
    DOI:10.1515/znb-2003-0808
    日期:2003.8.1

    Penta-O-pivaloyl-galactopyranose and tetra-O-pivaloyl-galactopyranosyl bromide after electrophilic activation reacted with 6-O-protected 2-azido-galactosides to give the precursor structures of the Thomsen-Friedenreich antigen disaccharide with high regioselectivity, but low yield.With 4,6-Obenzylidene protected 2-azidogalactosides and 2-O-pivaloyl phenylthio galactosides, T-antigen disaccharides of this type were obtained in good yields. Glycosylation reactions of 4,6-O-benzylidene protected glucosamine derivatives with O-pivaloyl protected galactosyl bromide efficiently gave lactolactosamine disaccharides. Even a thioglycoside was efficiently galactosylated by this method resulting in the formation of a disaccharide thioglycoside useful itself as a potential glycosyl donor.

    Penta-O-pivaloyl-galactopyranose和tetra-O-pivaloyl-galactopyranosyl在亲电活化后与6-O-保护的2-azido-galactosides反应,高选择性地形成Thomsen-Friedenreich抗原二糖的前体结构,但产率较低。使用4,6-Obenzylidene保护的2-azidogalactosides和2-O-pivaloyl基半乳苷,可以得到这种类型的T-抗原二糖,产率较高。4,6-O-benzylidene保护的葡萄糖基衍生物与O-pivaloyl保护的半乳苷的糖基化反应有效地产生了乳糖二糖。甚至通过这种方法,一种代糖苷也可以有效地被半乳苷化,形成一种作为潜在糖基供体的二糖代糖苷。
  • Bukowski, Ralph; Morris, Laura M.; Woods, Robert J., European Journal of Organic Chemistry, 2001, # 14, p. 2697 - 2705
    作者:Bukowski, Ralph、Morris, Laura M.、Woods, Robert J.、Weimar, Thomas
    DOI:——
    日期:——
  • Chemoselectively template-assembled glycopeptide presenting clustered cancer related T-antigen
    作者:Olivier Renaudet、Pascal Dumy
    DOI:10.1016/j.tetlet.2003.10.126
    日期:2004.1
    The first synthesis of the tumor-associated alpha-aminooxy T-antigen 1, a relevant recognition motif for the direct construction of multitopic carbohydrate architecture of biological interest is described. The usefulness of this building block is emphasized with the efficient preparation through oxime ligation of a neoglycopeptide cluster, which is readily suitable for evaluating the role of multivalency in antigen presentation to the immune system from an anticancer vaccine perspective. (C) 2003 Elsevier Ltd. All rights reserved.
  • Synthesis of a S-linked heparan sulfate trisaccharide as the substrate mimic of heparanase
    作者:Hongzhi Cao、Biao Yu
    DOI:10.1016/j.tetlet.2005.04.088
    日期:2005.6
    An approach to the Construction of the beta-(1 -> 4)-S-linkage between a glucuronic and a glucosamine unit, and then to the synthesis of a heparan sulfate trisaccharide containing such a linkage (1) as a nonhydrolyzable substrate mimic of heparanase was developed. (c) 2005 Elsevier Ltd. All rights reserved.
查看更多